Erratum: Evolution of cancer stem-like cells in endocrine-resistant metastatic breast cancers is mediated by stromal microvesicles (Cancer Research (2017) 77 (1927–1941) DOI: 10.1158/0008-5472.CAN-16-2129);Evolution of cancer stem-like cells in endocrine-resistant metastatic breast cancers is mediated by stromal microvesicles

Cancer Research

Volumn 77, Issue 8, 2017, Pages 1927-1941

  Sansone, Pasquale ^a   Berishaj, Marjan ^a   Rajasekhar, Vinagolu K ^a   Ceccarelli, Claudio ^b   Chang, Qing ^a   Strillacci, Antonio ^a,c   Savini, Claudia ^a,b,d   Shapiro, Lauren ^e   Bowman, Robert L ^a   Mastroleo, Chiara ^a   De Carolis, Sabrina ^b,d   Daly, Laura ^a   Benito Martin, Alberto ^f   Perna, Fabiana ^a   Fabbri, Nicola ^a   Healey, John H ^a   Spisni, Enzo ^c   Cricca, Monica ^b   Lyden, David ^a,f,g   Bonaf, Massimiliano ^b,e   Bromberg, Jacqueline ^a,g   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b AlmaMater Studiorum ^*  (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e KAISER PERMANENTE   (United States)

^f Drukier Institute for Children's Health   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FULVESTRANT; INTERLEUKIN 6; MICRORNA 221; STAT3 PROTEIN; TOCILIZUMAB; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRADIOL; IL6 PROTEIN, HUMAN; MICRORNA; MIRN221 MICRORNA, HUMAN; STAT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; CANCER ASSOCIATED FIBROBLAST; CANCER STEM CELL; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA ISOLATION; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SEQUENCE; HORMONAL THERAPY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; METASTATIC BREAST CANCER; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANIMAL; BREAST NEOPLASMS; CASE CONTROL STUDY; DRUG RESISTANCE; FEMALE; GENETICS; HELA CELL LINE; MCF-7 CELL LINE; MEMBRANE MICROPARTICLE; METABOLISM; NEOPLASM; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; STROMA CELL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CANCER-ASSOCIATED FIBROBLASTS; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; FEMALE; HELA CELLS; HETEROGRAFTS; HUMANS; INTERLEUKIN-6; MCF-7 CELLS; MICE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; NEOPLASMS, HORMONE-DEPENDENT; NEOPLASTIC STEM CELLS; STAT3 TRANSCRIPTION FACTOR; STROMAL CELLS;

EID: 85018219170     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-17-2427     Document Type: Erratum

References (54)

1. Yu DD, Wu Y, Shen HY, Lv MM, Chen WX, Zhang XH, et al. Exosomes in development, metastasis and drug resistance of breast cancer. Cancer Sci 2015;106:959-64.
2. Challagundla KB, Wise PM, Neviani P, Chava H, Murtadha M, Xu T, et al. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. J Natl Cancer Inst 2015;107:186-91.
3. Nouraee N, Mowla SJ, Calin GA. Tracking miRNAs' footprints in tumor-microenvironment interactions: Insights and implications for targeted cancer therapy. Genes Chromosomes Cancer 2015; 54:335-52.
4. Haslam SZ, Woodward TL.Host microenvironment in breast cancer development: epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland. Breast Cancer Res 2003;5:208-15.
5. Sansone P, Ceccarelli C, Berishaj M, Chang Q, Rajasekhar VK, Perna F, et al. Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nat Commun 2016;7:10442.
6. Dalerba P, Clarke MF. Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 2007;1:241-2.
7. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1:313-23.
8. Vermeulen L, de Sousa e Melo F, Richel DJ, Medema JP. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 2012;13:e83-9.
9. Borovski T, De Sousa E Melo F, Vermeulen L, Medema JP. Cancer stem cell niche: The place to be. Cancer Res 2011;71:634-9.
10. Sansone P, Storci G, Giovannini C, Pandolfi S, Pianetti S, Taffurelli M, et al. p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells 2007;25:807-15.
11. Chang Q, Bournazou E, Sansone P, BerishajM, Gao SP, Daly L, et al. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 2013;15:848-62.
12. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004;6:17-32.
13. Strillacci A, Griffoni C, Sansone P, Paterini P, Piazzi G, Lazzarini G, et al. miR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 2009; 315:1439-47.
14. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Realtime quantification ofmicroRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005;33:e179.
15. D'Anello L, Pasquale Sansone, Gianluca Storci, Valentina Mitrugno, Gabriele D'Uva, Pasquale Chieco, et al. Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells. Mol Cancer 2010;9:300.
16. Al-Rakan MA, Colak D, Hendrayani SF, Al-Bakheet A, Al-Mohanna FH, Kaya N, et al. Breast stromal fibroblasts from histologically normal surgical margins are pro-carcinogenic. J Pathol 2013;231:457-65.
17. Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun 2016;7:11150.
18. Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang W-C, et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 2015;527:100-4.
19. Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T, et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell 2014;159:499-513.
20. Toy W, Shen Y, WonH, Green B, Sakr RA, WillM, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013;45:1439-45.
21. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011;62:233-47.
22. Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 2010;16:1486-97.
23. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 2010;28:4111-9.
24. Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011;30:1082-97.
25. Simoes BM, O'Brien CS, Eyre R, Silva A, Yu L, Sarmiento-Castro A, et al. Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity. Cell Rep 2015; 12:1968-77.
26. Pedersen LG, Castelruiz Y, Jacobsen S, Aasted B. Identification of monoclonal antibodies that cross-react with cytokines from different animal species. Vet Immunol Immunopathol 2002;88:111-122.
27. Zhang XH, Jin X, Malladi S, Zou Y, Wen YH, Brogi E, et al. Selection of bone metastasis seeds bymesenchymal signals in the primary tumor stroma.Cell 2013;154:1060-73.
28. Zhao R, Wu J, Jia W, Gong C, Yu F, Ren Z, et al. Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie 2011;34: 675-80.
29. Haughian JM, PintoMP, Harrell JC, Bliesner BS, Joensuu KM, DyeWW, et al. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proc Natl Acad Sci U S A 2012;109: 2742-7.
30. Bergamaschi A, Madak-Erdogan Z, Kim YJ, Choi YL, Lu H, Katzenellenbogen BS. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells. Breast Cancer Res 2014;16:436.
31. Magnani L, Stoeck A, Zhang X, Lanczky A, Mirabella AC, Wang TL, et al. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad SciUS A 2013;110: E1490-9.
32. Lombardo Y, Faronato M, Filipovic A, Vircillo V, Magnani L, Coombes RC. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. Breast Cancer Res 2014;16:R62.
33. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-63.
34. Nagasaki T, Hara M, Nakanishi H, Takahashi H, Sato M, Takeyama H. Interleukin-6 released by colon cancer-Associated fibroblasts is critical for tumour angiogenesis: Anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer 2014;110:469-78.
35. Shah SH, Miller P, Garcia-Contreras M, Ao Z, Machlin L, Issa E, et al. Hierarchical paracrine interaction of breast cancer associated fibroblasts with cancer cells via hMAPK-microRNAs to drive ER-negative breast cancer phenotype. Cancer Biol Ther 2015;16:1671-81.
36. Gilani RA, Kazi AA, Shah P, Schech AJ, Chumsri S, Sabnis G, et al. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat 2012;135:681-92.
37. Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports 2014;2:78-91.
38. Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 2015;47:320-9.
39. Diaz LA Jr, Williams R, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
40. Sjostrom AE, Sandblad L, Uhlin BE, Wai SN. Membrane vesicle-mediated release of bacterial RNA. Sci Rep 2015;5:15329.
41. Ren G, Esposito M, Kang Y. Bone metastasis and the metastatic niche. J Mol Med 2015;93:1203-12.
42. Esposito M, Kang Y. Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther 2014;141:222-33.
43. Luo X, Fu Y, Loza AJ, Murali B, Leahy KM, Ruhland MK, et al. Stromalinitiated changes in the bone promote metastatic niche development. Cell Rep 2016;14:82-92.
44. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007;117:3988-4002.
45. Korkaya H, Kim G-i, Davis A, Malik F, Henry NL, Ithimakin S, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+breast cancer by expanding the cancer stem cell population.Mol Cell 2012;47:570-84.
46. Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, et al. Pancreatic cancer-Associated stellate cells promote differentiation of myeloid-derived suppressorcellsinaSTAT3-dependentmanner.CancerRes2013;73:3007-18.
47. Shintani Y, Fujiwara A, Kimura T, Kawamura T, Funaki S, Minami M, et al. IL-6 Secreted from cancer-Associated fibroblasts mediates chemoresistance in NSCLC by increasing epithelial-mesenchymal transition signaling. J Thorac Oncol 2016;11:1482-92.
48. Paulsson J, Micke P. Prognostic relevance of cancer-Associated fibroblasts in human cancer. Semin Cancer Biol 2014;25:61-8.
49. Cassidy JW, Caldas C, Bruna A. Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Res 2015;75:2963-8.
50. Coleman REClinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-6249s.
51. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-Term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-16.
52. Baselga J, Campone M, Piccart M, Burris HAIII, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
53. Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H, et al. Precisionmedicine for metastatic breast cancer-limitations and solutions. Nat Rev Clin Oncol 2015;12:693-704.
54. Bertolini G, D'Amico L, Moro M, Landoni E, Perego P, Miceli R, et al. Microenvironment-modulated metastatic CD133+/CXCR4+/EpCAMlung cancer-initiating cells sustain tumor dissemination and correlate with poor prognosis. Cancer Res 2015;75:3636-49.